M&A Deal Summary

ProMed Acquires SpineThera - cGMP Manufacturing Operational Assets

On April 3, 2024, ProMed acquired life science company SpineThera - cGMP Manufacturing Operational Assets from SpineThera

Acquisition Highlights
  • This is ProMed’s 1st transaction in the Life Science sector.
  • This is ProMed’s 1st transaction in the United States.
  • This is ProMed’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2024-04-03
Target SpineThera - cGMP Manufacturing Operational Assets
Sector Life Science
Buyer(s) ProMed
Sellers(s) SpineThera
Deal Type Divestiture

Target

SpineThera - cGMP Manufacturing Operational Assets

Medical Alley, Minnesota, United States
SpineThera's cGMP Manufacturing Operational Assets, a controlled environment manufacturing suite and process equipment that provide a robust manufacturing process supported by a cGMP quality management system and a highly experienced CMC team.

Search 193,103 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ProMed

Plymouth, Minnesota, United States

website

Category Company
Founded 1989
Sector Life Science
DESCRIPTION

ProMed is a contract manufacturer of polymer-based drug releasing dosage forms and combination device components. ProMed was founded in 1989 and is based in Plymouth, Minnesota.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1

Seller(S) 1

SELLER

SpineThera

Plymouth, Minnesota, United States

website

Category Company
Founded 2012
Sector Life Science
DESCRIPTION

SpineThera, Inc. designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug. The company was incorporated in 2012 and is based in Plymouth, Minnesota.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal